Invitae Acquires ArcherDX to Build a Precision Oncology Genetics Platform

Invitae Acquires YouScript and Genelex

March 10, 2020

Healthcare Services

Invitae Corporation has agreed to acquire YouScript, a clinical decision support and analytics platform, for approximately $79.3 million (cash and stock) and Genelex, a pharmacogenetic testing laboratory, for approximately $20.7 million in Invitae common stock plus potential milestone shares. The acquisitions integrate Genelex's pharmacogenetic testing and YouScript's real-time prescribing decision support into Invitae's genetics offerings to accelerate use of pharmacogenetics at the point of care.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.

Exact Sciences Acquires Paradigm Diagnostics and Viomics

March 3, 2020

Healthcare Services

Exact Sciences Corp. has completed the acquisitions of Phoenix-based Paradigm Diagnostics, Inc. and Viomics, Inc., adding a late-stage therapy selection genomic profiling test, a scalable clinical lab, and sequencing/biomarker discovery capabilities to its precision oncology portfolio. The deals (financial terms largely undisclosed in the company release) bring Paradigm and Viomics into Exact Sciences’ research and commercial platform to accelerate tissue- and blood-based advanced cancer diagnostics.

Veritas Genetics Acquires Curoverse

August 3, 2017

Biotechnology

Veritas Genetics has acquired Boston-based Curoverse, the creator of the Arvados open-source genomic data platform, for an undisclosed amount. The acquisition brings Curoverse’s bioinformatics, data-management and AI/ML capabilities in-house to expand Veritas’s capacity for large-scale genome interpretation and deploy machine learning across millions of genomes.

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Biotechnology

AbbVie has entered into a definitive agreement to acquire ImmunoGen for $31.26 per share in cash, valuing the company at approximately $10.1 billion. The deal gives AbbVie commercial rights to ELAHERE (mirvetuximab soravtansine-gynx) and ImmunoGen's ADC pipeline, expanding AbbVie's oncology capabilities; the transaction is expected to close in mid-2024 subject to shareholder and regulatory approvals.

Tesis Biosciences Acquires Genome Explorations

February 16, 2022

Biotechnology

Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.